Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

As interest in psychedelic medicine grows, Big Pharma sits on the sidelines

By Brian Buntz | May 21, 2021

Psychedelics

Image by Ben Johnson from Pixabay

While Big Pharma has yet to embrace psychedelics as potential treatments for depression and other psychiatric disorders, interest in psychedelic medicine is building. 

Earlier this month, Nature Medicine published a Phase 3 study indicating that psychotherapy assisted with methyl​enedioxy​methamphetamine (MDMA) was a more effective treatment for post-traumatic stress disorder (PTSD) than therapy alone. The study authors concluded that MDMA yielded a larger effect size than antidepressants Zoloft (sertraline) and Paxil (paroxetine).

The FDA granted Breakthrough Therapy Designation to MDMA-assisted psychotherapy for PTSD in 2017. Approval could come in 2023, according to The New York Times. 

[Related: Debate series considers the therapeutic promise and pitfalls of psychedelics]

Last month, NEJM summarized the results of a Phase 2 study that found that psilocybin was superior to escitalopram (Lexapro) in treating depression. 

Johnson & Johnson (NYSE:JNJ) scored an FDA approval for its ketamine-related Spravato for treatment-resistant depression. 

Many mental health experts, however, still have reservations about using traditional psychedelics to treat psychiatric disorders. The possibility of prescription psychedelics could fuel illicit use of those drugs. Such is the case for drugs such as Adderall and Ritalin used to treat attention-deficit/hyperactivity disorder (ADHD). 

The U.S. Drug Enforcement Administration labels most psychedelics as Schedule 1 or 2 drugs, making their use illegal outside of clinical research.

Still, interest from (predominately small) pharmaceutical companies in psychedelics is building.

MindMed (NSDQ:MNMD) recently announced it is launching a trial to explore the therapeutic potential of mescaline after receiving approval from a Swiss ethics committee. 

Cybin (OTCMKTS: CLXPF) is launching a Phase 2 clinical study to test a sublingual formulation of psilocybin for people with major depressive disorder.

Kelowna, Canada–based Tryp Therapeutics (CNSX:TRYP) is currently doing preclinical research on psilocybin for fibromyalgia, eating disorders and chronic pain. 

Privately-held Cognistx (Pittsburgh) and MagicMed (Calgary, Canada) are partnering to develop an AI platform to facilitate research on psychedelic-derived pharmaceuticals.

Still, it remains to be determined whether psychedelics will disrupt the psychotropic drug market or whether the growing investment in the space will turn out to be a bad trip. 


Filed Under: clinical trials, Drug Discovery, Psychiatric/psychotropic drugs
Tagged With: Big Pharma, Cognistx, Cybin, escitalopram, FDA, Lexapro, MagicMed, MDMA, methyl​enedioxy​methamphetamine, MindMed, Paxil, psychotherapy, Tryp Therapeutics, Zoloft
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE